Brian Goff - 13 Jun 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
13 Jun 2024
Net transactions value
$0
Form type
4
Filing time
17 Jun 2024, 17:14:33 UTC
Previous filing
07 Jun 2024
Next filing
12 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +15,409 $0.000000 15,409 13 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +22,297 $0.000000 22,297 13 Jun 2024 Common Stock 22,297 $25.96 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on June 13, 2024 with respect to 22,297 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on June 13, 2025 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.